1,4-dihydroxy Quininib Activates Ferroptosis Pathways in Metastatic Uveal Melanoma and Reveals a Novel Prognostic Biomarker Signature

ABSTRACT: Uveal melanoma (UM) is an ocular cancer, with propensity for lethal liver metastases. When metastatic UM (MUM) occurs, as few as 8% of patients survive beyond two years. Efficacious treatments for MUM are urgently needed. 1,4-dihydroxy quininib, a cysteinyl leukotriene receptor 1 (CysLT1) antagonist, alters UM cancer hallmarks in vitro, ex vivo and in vivo. Here, we investigated the 1,4-dihydroxy quininib mechanism of action and its translational potential in MUM.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Choroidal Melanocyte

DISEASE(S): Uveal Melanoma

SUBMITTER: Eugene Dillon  

LAB HEAD: Brendan Kennedy

PROVIDER: PXD046822 | Pride | 2024-06-16

REPOSITORIES: Pride